🔎 Trials Near Me

Beranda › Leukemia › Tennessee

Uji klinis Leukemia di Tennessee

14 studi untuk Leukemia mencari peserta di lokasi di Tennessee.

Kota di Tennessee

Teks studi resmi (Bahasa Inggris)

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

  • Quetzal Site 12, Nashville
Menerima pesertaFase 3
Usia 18 hingga 71 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07504458

A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia

  • St. Jude Children's Research Hospital, Memphis
Menerima pesertaFase 1
Hingga usia 25 · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06810583

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

  • Sarah Cannon Research Institute, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07284433

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • Baptist Clinical Research Institute, Memphis
  • Tennessee Oncology, Nashville
  • TriStar Centennial Medical Center, Nashville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • Vanderbilt University Medical Center, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT06001788

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • TriStar BMT, Nashville
Menerima pesertaFase 1/2
Usia 13 hingga 90 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06533579

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • Vanderbilt University, Ingram Cancer Center, Nashville
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT07216443

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Vanderbilt University Medical Center, Nashville
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Apr 2026 · NCT04256317

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • Baptist Clinical Research Institute, Memphis
Menerima pesertaFase 1/2
Usia 12 hingga 95 · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT04329728

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • TriStar Bone Marrow Transplant, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Mar 2026 · NCT05735184

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • Baptist (BHMCC), Memphis
  • Vanderbilt-Ingram Cancer Center, Nashville
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT05366881

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Memphis
  • Massive Bio SYNERGY-AI site, Nashville
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

  • Sarah Cannon Research Institute, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2025 · NCT06501196

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

  • TriStar Bone Marrow Transplant, Nashville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Nov 2024 · NCT06034275

Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.